NCT07316088
Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentOui Therapeutics, Inc.
~40 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:OTX-601 Digital TherapeuticOTX-003 Comparator app
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in PTSD symptoms between baseline and week 7
Measured over Baseline, Week 7
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Posttraumatic stress disorder (PTSD) diagnosis
Anxiety Sensitivity Index 3 (ASI-3) scores above 24
PTSD Checklist for DSM-V (PCL-5) scores above 30
Understands and speaks English
Access to a smartphone that is connected to the internet
Exclusion
Score of 24 or lower on the ASI-3
Score of 30 and below on the PCL-5
No PTSD diagnosis
Active psychosis
Acute intoxication during study baseline
Enrolled in another treatment research study
Medical illness that would prevent the completion of interoceptive exposure exercises
What this trial measures
- Change in PTSD symptoms between baseline and week 7Baseline, Week 7
Change in PTSD symptoms will be ascertained with the PTSD Checklist for DSM-V (PCL-5). The PCL-5 total score ranges from 0 to 80, with higher scores indicating more severe symptoms.